DDInter915 DDInter669
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Indacaterol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is palliated by {v} (Compound) Ephedrine
Ephedrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Indacaterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is upregulated by {v} (Compound) Losartan
Losartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Indacaterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is downregulated by {v} (Compound) Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ertugliflozin
Indacaterol {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ertugliflozin
Indacaterol {u} (Compound) causes {v} (Side Effect) Rhinorrhoea
Rhinorrhoea {u} (Side Effect) is caused by {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Ertugliflozin
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indacaterol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is palliated by Ephedrine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indacaterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indacaterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Losartan (Compound) and Losartan may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indacaterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is downregulated by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Indacaterol (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Indacaterol (Compound) causes Rhinorrhoea (Side Effect) and Rhinorrhoea (Side Effect) is caused by Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Ertugliflozin